A Comparative In Vivo Scrutiny of Biosynthesized Copper and Zinc Oxide Nanoparticles by Intraperitoneal and Intravenous Administration Routes in Rats

Table 9 Weight of organs or organ index (O_X) for rat treated with Bio-CuNPs and Bio-ZnONPs through intraperitoneal and intravenous route of administration for 14th day of observation

Tests	Group I: Bio-CuNPs			Group II: Bio-ZnONPs			Control
Tests	NOAEC	IC₅₀	TLC	NOAEC	IC₅₀	TLC
Heart (H_X)
i/v	0.96 ± 0.06	0.48 ± 0.07	0.22 ± 0.075	1.1 ± 0.04	1.03 ± 0.065	1.25 ± 0.024	1 ± 0.02
i/p	1.9 ± 0.09	1.25 ± 0.0344	1.143 ± 0.023	1.23 ± 0.032	0.98 ± 0.077	0.94 ± 0.065	1.4 ± 0.05
Liver (Li_X)
i/v	I.25 ± 0.043	0.92 ± 0.06	0.48 ± 0.049	1.67 ± 0.026	1.56 ± 0.093	1.47 ± 0.086	1.8 ± 0.043
i/p	1.44 ± 0.05	1.23 ± 0.08	1.08 ± 0.099	1.54 ± 0.07	1.34 ± 0.032	1.27 ± 0.0289	1.67 ± 0.032
Spleen (S_X)
i/v	0.59 ± 0.07	0.47 ± 0.09	0.265 ± 0.043	1.45 ± 0.019	0.97 ± 0.006	0.87 ± 0.054	1.16 ± 0.028
i/p	087 ± 0.01	0.63 ± 0.054	0.58 ± 0.052	1.38 ± 0.054	0.66 ± 0.053	0.65 ± 0.039	1.18 ± 0.067
Lungs (Lu_X)
i/v	0.87 ± 0.065	0.77 ± 0.076	0.42 ± 0.081	2.14 ± 0.098	.78 ± 0.033	1.54 ± 0.044	1.56 ± 0.082
i/p	0.86 ± 0.086	0.67 ± 0.012	0.75 ± 0.093	2.06 ± 0.12	0.94 ± 0.054	0.78 ± 0.067	1.72 ± 0.028
Kidneys (K_X)
i/v	0.64 ± 0.03	0.5 ± 0.043	0.35 ± 0.073	2.4 ± 0.156	2.10 ± 0.028	1.78 ± 0.026	1.23 ± 0.099
i/p	0.83 ± 0.06	0.8 ± 0.053	0.65 ± 0.043	1.98 ± 0.087	0.34 ± 0.054	0.88 ± 0.058	1.52 ± 0.091
Thymus (T_X)
i/v	0.21 ± 0.09	0.18 ± 0.027	0.11 ± 0.053	0.167 ± 0.034	0.15 ± 0.034	0.142 ± 0.094	0.18 ± 0.076
i/p	0.2 ± 0.03	0.22 ± 0.036	0.18 ± 0.09	0.178 ± 0.053	0.112 ± 0.028	0.13 ± 0.027	0.16 ± 0.045
Brain (B_X)
i/v	1.92 ± 0.05	0.72 ± 0.072	0.75 ± 0.001	2.3 ± 0.044	1.76 ± 0.095	1.54 ± 0.079	1.89 ± 0.092
i/p	1.76 ± 0.086	1.25 ± 0.058	1.22 ± 0.064	2.1 ± 0.075	1.21 ± 0.053	1.02 ± 0.091	1.72 ± 0.087

All data are expressed in mean ± SD of the mean of the three independent experiments; each was carried out in triplicate, N = 6 rats per group